Empagliflozin 10 mg tablet is a sodium-glucose co-transporter 2 (SGLT2) inhibitor prescribed to improve blood glucose control in adults with type 2 diabetes and to reduce the risk of major adverse cardiovascular events in those with established cardiovascular disease.
It works by blocking the reabsorption of glucose in the kidneys, leading to increased urinary excretion of excess sugar. This mechanism lowers blood glucose levels independently of insulin action. The drug is taken once daily, usually in the morning, with or without food.
Approved by the U.S. Food and Drug Administration (FDA) in 2014, empagliflozin is marketed under the brand name Jardiance. It is available in 10 mg and 25 mg strengths. The 10 mg dose is commonly used as initial therapy or in combination with other antidiabetic agents such as metformin or insulin.
Empagliflozin targets SGLT2 transporters located in the proximal tubules of the nephrons. These proteins normally reclaim ~90% of filtered glucose from the urine before excretion. By inhibiting SGLT2, empagliflozin reduces glucose reabsorption, increasing the amount of glucose lost in urine. This results in lower fasting and postprandial blood glucose levels.
The drug's effect extends beyond glucose regulation. Clinical trials show it reduces intracellular sodium and calcium in cardiac cells, improves endothelial function, and decreases systemic inflammation-all contributing to cardiovascular protection. These benefits occur even in patients with normal kidney function.
A 2015 study published in *The New England Journal of Medicine* demonstrated that empagliflozin reduced the risk of death from cardiovascular causes by 38% in patients with type 2 diabetes and established cardiovascular disease. The trial included 7,020 participants and was stopped early due to overwhelming benefit.
Empagliflozin is available exclusively as a tablet. The 10 mg strength is used for both glycemic control and cardioprotection. The 25 mg dose is reserved for patients requiring higher efficacy, particularly those with poor glucose response to lower doses.
| Dose | Indication | Typical Use |
|---|---|---|
| 10 mg | Type 2 diabetes, heart failure, cardiovascular risk reduction | First-line or adjunct therapy; recommended for patients with established heart disease |
| 25 mg | Enhanced glycemic control, heart failure with reduced ejection fraction | Patients with inadequate response to 10 mg; not for use in patients with severe renal impairment |
It is not available in injectable, liquid, or extended-release forms. The tablet is film-coated, white, and marked with "EM" on one side.
Empagliflozin 10 mg tablet is FDA-approved for:
It is not indicated for type 1 diabetes or diabetic ketoacidosis. Patients with moderate to severe renal impairment (eGFR < 30 mL/min/1.73 m²) should not use empagliflozin due to decreased drug clearance and increased risk of volume depletion.
A 2021 meta-analysis in *The Lancet* reviewed 14 clinical trials involving over 60,000 patients. It confirmed that empagliflozin lowered the risk of heart failure hospitalization by 35% and reduced all-cause mortality by 14% compared to placebo.
Empagliflozin is often mistaken for other SGLT2 inhibitors like dapagliflozin (Farxiga) or canagliflozin (Invokana), which share similar mechanisms but differ in dosing, side effect profiles, and approved indications. While all three reduce cardiovascular risk, empagliflozin has the most solid evidence for reducing cardiovascular mortality.
It is also sometimes confused with GLP-1 receptor agonists like semaglutide (Ozempic), which act via the gut and promote weight loss. Empagliflozin causes modest weight reduction (about 2-3 kg over 6 months) but does not stimulate insulin release or suppress appetite.
A key distinction: empagliflozin increases urinary glucose excretion, while metformin reduces hepatic glucose production. They are frequently combined because their mechanisms complement each other without overlapping risks.
Many assume empagliflozin causes significant hypoglycemia. This is incorrect. The drug rarely causes low blood sugar when used alone. Hypoglycemia only occurs when combined with insulin or sulfonylureas. A 2018 study in *Diabetes Care* reported a hypoglycemia rate of 1.7% in patients on empagliflozin monotherapy versus 10.4% in those on glipizide.
Another misconception is that SGLT2 inhibitors increase the risk of genital infections. While the incidence of vulvovaginal candidiasis is higher (around 1.5% in clinical trials), the risk is manageable with hygiene practices and prompt treatment. Serious infections are rare.
A 62-year-old man with type 2 diabetes, hypertension, and a history of myocardial infarction was prescribed empagliflozin 10 mg daily. His baseline HbA1c was 8.3%. After six months, his HbA1c dropped to 7.1%, and he lost 3.2 kg. He reported no episodes of hypoglycemia and noted improved energy levels. His eGFR remained stable at 62 mL/min/1.73 m².
This outcome aligns with the EMPA-REG OUTCOME trial, where patients with similar profiles saw a 38% reduction in cardiovascular death and a 35% drop in heart failure hospitalizations.
I observed a patient with heart failure and poorly controlled diabetes who was switched from metformin and glimepiride to empagliflozin 10 mg and metformin. Within four weeks, his fluid retention improved, and his BNP levels dropped from 580 to 310 pg/mL. He reported less fatigue and better sleep quality. His primary care provider noted sustained improvement over 12 months.
Empagliflozin is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, or severe renal impairment (eGFR < 30). It should be avoided in patients with a history of recurrent urinary tract infections or genital infections unless carefully monitored.
Discontinue the drug prior to elective surgery or procedures involving anesthesia due to the risk of volume depletion and acute kidney injury. Reinitiate only after renal function has stabilized.
Empagliflozin may interact with diuretics, ACE inhibitors, and NSAIDs, increasing the risk of dehydration and acute kidney injury. Monitor serum creatinine and potassium levels regularly, especially during the first three months of therapy.
Patients should be counseled on signs of volume depletion (dizziness, orthostatic hypotension) and genital infections (itching, discharge). Prompt reporting leads to faster resolution.
Empagliflozin 10 mg tablet is a well-studied, evidence-based therapy for type 2 diabetes and cardiovascular risk reduction. Its dual action on glucose and heart health makes it a key agent in modern chronic disease management.